Q2 EPS Forecast for PROCEPT BioRobotics Decreased by Analyst

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q2 2025 earnings estimates for PROCEPT BioRobotics in a research note issued on Monday, April 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.43) for the quarter, down from their previous estimate of ($0.39). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics' Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.54) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.23) EPS and FY2029 earnings at $0.23 EPS.

Other analysts have also issued research reports about the company. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Bank of America decreased their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

PROCEPT BioRobotics Trading Up 5.2 %

PRCT traded up $2.77 on Thursday, hitting $55.62. 930,808 shares of the company were exchanged, compared to its average volume of 805,885. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The firm has a fifty day simple moving average of $56.75 and a two-hundred day simple moving average of $73.36. The stock has a market capitalization of $3.08 billion, a PE ratio of -28.52 and a beta of 1.09. PROCEPT BioRobotics has a 12 month low of $47.04 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.04. The business had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.51) earnings per share.

Insider Activity

In related news, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,455 shares of company stock valued at $368,322. Corporate insiders own 17.40% of the company's stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors and hedge funds have recently made changes to their positions in PRCT. Raleigh Capital Management Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $32,000. Thematics Asset Management bought a new stake in PROCEPT BioRobotics in the fourth quarter worth $46,000. CWM LLC increased its holdings in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company's stock valued at $51,000 after acquiring an additional 358 shares in the last quarter. Signaturefd LLC raised its position in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares during the last quarter. Finally, IFP Advisors Inc purchased a new position in shares of PROCEPT BioRobotics in the 4th quarter worth about $58,000. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).